

SENATE BILL 189

J3

2lr0055

(PRE-FILED)

By: **Chair, Judicial Proceedings Committee (By Request – Departmental – Health)**

Requested: October 5, 2021

Introduced and read first time: January 12, 2022

Assigned to: Judicial Proceedings

A BILL ENTITLED

1 AN ACT concerning

2 **Controlled Substances – Schedules**

3 FOR the purpose of altering the lists of substances designated as controlled dangerous
4 substances under certain schedules under the Maryland Controlled Dangerous
5 Substances Act; and generally relating to schedules for controlled dangerous
6 substances.

7 BY repealing and reenacting, with amendments,

8 Article – Criminal Law

9 Section 5–402 through 5–406

10 Annotated Code of Maryland

11 (2021 Replacement Volume and 2021 Supplement)

12 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,

13 That the Laws of Maryland read as follows:

14 **Article – Criminal Law**

15 5–402.

16 (a) Schedule I consists of each controlled dangerous substance:

17 (1) listed in this section;

18 (2) added to Schedule I by the Department under § 5–202(b) of this title; or

19 (3) designated as a Schedule I controlled dangerous substance by the
20 federal government unless the Department objects under § 5–202(f) of this title.

21 (b) Unless specifically excepted under this subtitle or listed in another schedule,

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



1 any of the following opiates, including their isomers, including optical and geometric
 2 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the
 3 existence of such isomers, esters, ethers, or salts is possible within the specific chemical
 4 designation, are substances listed in Schedule I:

- 5 (1) acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-
 6 piperidinyl]-N-phenylacetamide);
- 7 (2) acetylmethadol;
- 8 (3) acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
- 9 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide);
- 10 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl])
 11 benzamide;
- 12 (6) allylprodine;
- 13 (7) alphacetylmethadol, except levo-alphacetylmethadol;
- 14 (8) alphameprodine;
- 15 (9) alphamethadol;
- 16 (10) alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl
 17 -4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
- 18 (11) alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl
 19 -4-piperidinyl]-N-phenylpropanamide);
- 20 (12) benzethidine;
- 21 (13) betacetylmethadol;
- 22 (14) beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)
 23 -4-piperidinyl]-N-phenylpropanamide);
- 24 (15) beta-hydroxy-3-methylfentanyl **(N-[1-(2-HYDROXY-2-
 25 PHENYLETHYL)-3-METHYL-4-PIPERIDINYL]-N-PHENYLPROPANAMIDE);**
- 26 (16) **BETA-HYDROXYTHIOFENTANYL** (N-[1-[2-hydroxy-2-(thiophen-2-
 27 yl)ethyl]piperidin-4-yl]-N-phenylpropionamide);
- 28 (17) betameprodine;
- 29 (18) betamethadol;

1 **(19) BETA-METHYLFENTANYL** **(N-PHENYL-N-(1-(2**
2 **-PHENYLPROPYL)PIPERIDIN-4-YL)PROPIONAMIDE; ALSO KNOWN AS B-**
3 **METHYLFENTANYL);**

4 **(20) BETA'-PHENYL FENTANYL (N-(1-PHENETHYLPIPERIDIN-4-YL)**
5 **-N,3-DIPHENYLPROPANAMIDE; ALSO KNOWN AS B'-PHENYL FENTANYL;**
6 **3-PHENYLPROPANOYL FENTANYL);**

7 **[(19)] (21) betaprodine;**

8 **[(20)] (22) butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)**
9 **-N-phenylbutyramide);**

10 **[(21)] (23) clonitazene;**

11 **(24) CROTONYL FENTANYL ((E)-N-(1-PHENETHYLPIPERIDIN-4-YL)**
12 **-N-PHENYLBUT-2-ENAMIDE);**

13 **(25) CYCLOPENTYL FENTANYL (N-(1-PHENETHYLPIPERIDIN-4-YL)**
14 **-N-PHENYLCYCLOPENTANECARBOXAMIDE);**

15 **(26) CYCLOPROPYL FENTANYL (N-(1-PHENETHYLPIPERIDIN-4-YL)**
16 **-N-PHENYLCYCLOPROPANECARBOXAMIDE);**

17 **[(22)] (27) dextromoramide;**

18 **[(23)] (28) diampromide;**

19 **[(24)] (29) diethylthiambutene;**

20 **[(25)] (30) difenoxin;**

21 **[(26)] (31) dimenoxadol;**

22 **[(27)] (32) dimepheptanol;**

23 **[(28)] (33) dimethylthiambutene;**

24 **[(29)] (34) dioxaphetyl butyrate;**

25 **[(30)] (35) dipipanone;**

26 **[(31)] (36) ethylmethylthiambutene;**

1 [(32)] (37) etonitazene;

2 [(33)] (38) etoxeridine;

3 (39) FENTANYL CARBAMATE (ETHYL (1-PHENETHYLPIPERIDIN
4 -4-YL)(PHENYL)CARBAMATE);

5 [(34)] (40) 4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1
6 -phenethylpiperidin-4-yl)isobutyramide);

7 (41) 2'-FLUORO ORTHO-FLUOROFENTANYL (N-(1-(2
8 -FLUOROPHENETHYL)PIPERIDIN-4-YL)-N-(2-FLUOROPHENYL)PROPIONAMIDE;
9 ALSO KNOWN AS 2'-FLUORO 2-FLUOROFENTANYL);

10 [(35)] (42) furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N
11 -phenylfuran-2-carboxamide);

12 [(36)] (43) furethidine;

13 [(37)] (44) hydroxypethidine;

14 (45) ISOBUTYRYL FENTANYL (N-(1-PHENETHYLPIPERIDIN-4-YL)
15 -N-PHENYLISOBUTYRAMIDE);

16 [(38)] (46) ketobemidone;

17 [(39)] (47) levomoramide;

18 [(40)] (48) levophenacylmorphan;

19 (49) METHOXYACETYL FENTANYL (2-METHOXY-N-(1
20 -PHENETHYLPIPERIDIN-4-YL)-N-PHENYLACETAMIDE);

21 (50) 4'-METHYL ACETYL FENTANYL (N-(1-(4
22 -METHYLPHENETHYL)PIPERIDIN-4-YL)-N-PHENYLACETAMIDE);

23 [(41)] (51) 3-methylfentanyl (N-[3-methyl-1-(2-phenylethyl)
24 -4-piperidyl]-N-phenylpropanamide);

25 [(42)] (52) 3-methylthiofentanyl (N-[3
26 -METHYL-1-(2-THIENYLETHYL)-4-PIPERIDINYL]-N-PHENYLPROPANAMIDE);

27 [(43)] (53) morpheridine;

28 [(44)] (54) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);

1 [(65)] (88) trimeperidine; [and]

2 [(66)] (89) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N
3 - methylbenzamide); AND

4 (90) VALERYL FENTANYL (N-(1-PHENETHYLPIPERIDIN-4-YL)
5 -N-PHENYLPENTANAMIDE).

6 (c) Unless specifically excepted under this subtitle or listed in another schedule,
7 any of the following opium derivatives, including their salts, isomers, and salts of isomers,
8 whenever the existence of such salts, isomers, or salts of isomers is possible within the
9 specific chemical designation, are substances listed in Schedule I:

- 10 (1) acetorphine;
- 11 (2) acetyldihydrocodeine;
- 12 (3) benzylmorphine;
- 13 (4) codeine methylbromide;
- 14 (5) codeine-N-oxide;
- 15 (6) cyprenorphine;
- 16 (7) desomorphine;
- 17 (8) dihydromorphine;
- 18 (9) drotebanol;
- 19 (10) etorphine (except hydrochloride salt);
- 20 (11) heroin;
- 21 (12) hydromorphinol;
- 22 (13) methyldesorphine;
- 23 (14) methyldihydromorphine;
- 24 (15) morphine methylbromide;
- 25 (16) morphine methylsulfonate;
- 26 (17) morphine-N-oxide;

- 1 (18) myrophine;
- 2 (19) nicocodeine;
- 3 (20) nicomorphine;
- 4 (21) normorphine;
- 5 (22) pholcodine; and
- 6 (23) thebacon.

7 (d) Unless specifically excepted under this subtitle or listed in another schedule,
8 any material, compound, mixture, or preparation that contains any quantity of the
9 following hallucinogenic substances, or that contains any of its salts, isomers, including
10 optical, position, and geometric isomers, or salts of isomers, whenever the existence of such
11 salts, isomers, or salts of isomers is possible within the specific chemical designation, is a
12 substance listed in Schedule I:

- 13 (1) alpha-ethyltryptamine;
- 14 (2) 4-bromo-2,5-dimethoxy-amphetamine;
- 15 (3) 4-bromo-2,5-dimethoxyphenethylamine;
- 16 (4) 2,5-dimethoxyamphetamine;
- 17 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET);
- 18 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7);
- 19 (7) 4-methoxyamphetamine (PMA);
- 20 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 21 (9) 4-methyl-2,5-dimethoxy-amphetamine;
- 22 (10) 3,4-methylenedioxy amphetamine;
- 23 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 24 (12) 3,4-methylenedioxy-N-ethylamphetamine (MDA);
- 25 (13) N-hydroxy-3,4-methylenedioxyamphetamine;
- 26 (14) 3,4,5-trimethoxyamphetamine;

- 1 (15) 5-methoxy-N, N-dimethyltryptamine;
- 2 (16) alpha-methyltryptamine (AMT);
- 3 (17) bufotenine;
- 4 (18) diethyltryptamine (DET);
- 5 (19) dimethyltryptamine (DMT);
- 6 (20) 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT);
- 7 (21) ibogaine;
- 8 (22) lysergic acid diethylamide;
- 9 (23) marijuana;
- 10 (24) mescaline;
- 11 (25) parahexyl-7374;
- 12 (26) peyote (meaning all parts of the plant presently classified botanically
13 as *Lophophora williamsii* lemaire, whether growing or not, the seeds thereof, any extract
14 from any part of such plant, and every compound, manufacture, salt, derivative, mixture,
15 or preparation of such plant, its seeds, or extracts);
- 16 (27) N-ethyl-3-piperidyl benzilate;
- 17 (28) N-methyl-3-piperidyl benzilate;
- 18 (29) psilocybin;
- 19 (30) psilocyn;
- 20 (31) tetrahydrocannabinols;
- 21 (32) ethylamine analog of phencyclidine (N-ethyl-1
22 -phenylcyclohexylamine);
- 23 (33) pyrrolidine analog of phencyclidine (1-(1-phenylcyclohexyl)
24 -pyrrolidine);
- 25 (34) thiophene analog of phencyclidine (1-[1-(2-thienyl)-cyclohexyl]
26 -piperidine);

- 1 (35) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
- 2 (36) 4-methylmethcathinone (mephedrone);
- 3 (37) 3, 4-methylenedioxyprovalerone (MDPV);
- 4 (38) 2-(2,5-dimethoxy-4-ethylphenyl) ethanamine (2C-E);
- 5 (39) 2-(2,5-dimethoxy-4-methylphenyl) ethanamine (2C-D);
- 6 (40) 2-(4-chloro-2,5-dimethoxyphenyl) ethanamine (2C-C);
- 7 (41) 2-(4-iodo-2,5-dimethoxyphenyl) ethanamine (2C-I);
- 8 (42) 2-[4-(ethylthio)-2,5-dimethoxyphenyl] ethanamine (2C-T-2);
- 9 (43) 2-[4-(isopropylthio)-2,5-dimethoxyphenyl] ethanamine (2C-T-4);
- 10 (44) 2-(2,5-dimethoxyphenyl) ethanamine (2C-H);
- 11 (45) 2-(2,5-dimethoxy-4-nitro-phenyl) ethanamine (2C-N);
- 12 (46) 2-(2,5-dimethoxy-4-(n)-propylphenyl) ethanamine (2C-P);
- 13 (47) 3,4-methylenedioxy-N-methylcathinone (methylone);
- 14 (48) (1-pentyl-1H-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl) methanone
15 (UR-144);
- 16 (49) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)
17 methanone (5-fluoro-UR-144, XLR11);
- 18 (50) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA,
19 AKB48);
- 20 (51) quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22);
- 21 (52) quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro
22 - PB-22);
- 23 (53) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-
24 indazole-3-carboxamide (AB-FUBINACA);
- 25 (54) N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H
26 -indazole-3-carboxamide (ADB-PINACA);
- 27 (55) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine

1 (25I-NBOMe);

2 (56) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine
3 (25C-NBOMe);

4 (57) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine
5 (25B-NBOMe);

6 (58) marijuana extract (meaning an extract containing one or more
7 cannabinoids that has been derived from any plant of the genus cannabis, other than the
8 separated resin, whether crude or purified, obtained from the plant);

9 (59) 4-methyl-N-ethylcathinone (4-MEC);

10 (60) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);

11 (61) alpha-pyrrolidinopentiophenone (alpha-PVP);

12 (62) 1-(1,3-benzodioxol-5-yl)-2-(methylamino) butan-1-one (butylone);

13 (63) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);

14 (64) 1-(1,3-benzodioxol-5-yl)-2-(methylamino) pentan-1-one (pentylone);

15 (65) 4-fluoro-N-methylcathinone (flephedrone);

16 (66) 3-fluoro-N-methylcathinone (3-FMC);

17 (67) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone);

18 (68) alpha-pyrrolidinobutiophenone (alpha-PBP);

19 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-
20 indazole-3-carboxamide (AB-CHMINACA);

21 (70) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-
22 carboxamide (AB-PINACA);

23 (71) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone
24 (THJ-2201); [and]

25 (72) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-
26 1H-indazole-3-carboxamide (MAB-CHMINACA);

27 **(73) METHYL 2-(1-(5-FLUOROPENTYL)-1H-INDAZOLE-3**
28 **-CARBOXAMIDO)-3,3-DIMETHYLBUTANOATE (OTHER NAMES: 5F-ADB; 5F-**
29 **MDMB-PINACA);**

- 1 (74) METHYL 2-(1-(5-FLUOROPENTYL)-1H-INDAZOLE-3
2 -CARBOXAMIDO)-3-METHYLBUTANOATE (OTHER NAMES: 5F-AMB);
- 3 (75) N-(ADAMANTAN-1-YL)-1-(5-FLUOROPENTYL)-1H-INDAZOLE-
4 3-CARBOXAMIDE (OTHER NAMES: 5F-APINACA, 5F-AKB48);
- 5 (76) N-(1-AMINO-3,3-DIMETHYL-1-OXOBUTAN-2-YL)-1-(4-
6 FLUOROBENZYL)-1H-INDAZOLE-3-CARBOXAMIDE (OTHER NAMES: ADB-
7 FUBINACA);
- 8 (77) METHYL 2-(1-(CYCLOHEXYLMETHYL)-1H-INDOLE-3
9 -CARBOXAMIDO)-3,3-DIMETHYLBUTANOATE (OTHER NAMES: MDMBA-CHMICA,
10 MMB-CHMINACA);
- 11 (78) METHYL 2-(1-(4-FLUOROBENZYL)-1H-INDAZOLE-3
12 -CARBOXAMIDO)-3,3-DIMETHYLBUTANOATE (OTHER NAMES: MDMB-
13 FUBINACA);
- 14 (79) METHYL 2-(1-(4-FLUOROBENZYL)-1H-INDAZOLE-3
15 -CARBOXAMIDO)-3-METHYLBUTANOATE, (FUB-AMB, MMB-FUBINACA, AMB-
16 FUBINACA);
- 17 (80) 1-(1,3-BENZODIOXOL-5-YL)-2-(ETHYLAMINO)PROPAN-1-ONE
18 (ETHYLONE);
- 19 (81) NAPHTHALEN-1-YL 1-(5-FLUOROPENTYL)-1H-INDOLE-3-
20 CARBOXYLATE (OTHER NAMES: NM2201; CBL2201);
- 21 (82) N-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)-1-(5-
22 FLUOROPENTYL)-1H-INDAZOLE-3-CARBOXAMIDE (OTHER NAME: 5F-AB-
23 PINACA);
- 24 (83) 1-(4-CYANOBTYL)-N-(2-PHENYLPROPAN-2-YL)-1H-
25 INDAZOLE-3-CARBOXAMIDE (OTHER NAMES: 4-CN-CUMYL-BUTINACA; 4
26 -CYANO-CUMYL-BUTINACA; 4-CN-CUMYL BINACA; CUMYL-4-CN-
27 BINACA; SGT-78);
- 28 (84) METHYL 2-(1-(CYCLOHEXYLMETHYL)-1H-INDOLE-3
29 -CARBOXAMIDO)-3-METHYLBUTANOATE (OTHER NAMES: MMB-CHMICA; AMB-
30 CHMICA);
- 31 (85) 1-(5-FLUOROPENTYL)-N-(2-PHENYLPROPAN-2-YL)-1H-
32 PYRROLO[2,3B]PYRIDINE-3-CARBOXAMIDE (OTHER NAME: 5F-CUMYL-

1 **P7AICA);**

2 **(86) N-ETHYLPENTYLONE (OTHER NAMES: EPHYLONE, 1-(1,3-**
3 **BENZODIOXOL-5-YL)-2-(ETHYLAMINO)PENTAN-1-ONE);**

4 **(87) METHYL 2-(1-(4-FLUOROBUTYL)-1H-INDAZOLE-3**
5 **-CARBOXAMIDO)-3,3-DIMETHYLBUTANOATE (4F-MDMB-BINACA, 4F-MDMB-**
6 **BUTINACA); AND**

7 **(88) 1-(4-METHOXYPHENYL)-N-METHYLPROPAN-2-AMINE (OTHER**
8 **NAMES: PARA-METHOXYMETHAMPHETAMINE, PMMA).**

9 (e) Unless specifically excepted under this subtitle or listed in another schedule,
10 a material, compound, mixture, or preparation that contains any quantity of the following
11 substances having depressant effects on the central nervous system, or that contains its
12 salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of
13 isomers is possible within the specific chemical designation, is a substance listed in
14 Schedule I:

15 (1) gamma-hydroxybutyric acid (GHB);

16 (2) mecloqualone; and

17 (3) methaqualone.

18 (f) Unless specifically excepted or listed in another schedule, any material,
19 compound, mixture, or preparation that contains any quantity of the following substances
20 having a stimulant effect on the central nervous system, or that contains its salts, isomers,
21 or salts of isomers, is a substance listed in Schedule I:

22 (1) aminorex;

23 (2) N-benzylpiperazine (BZP);

24 (3) cathinone;

25 (4) fenethylamine;

26 (5) methcathinone;

27 (6) [(+)-cis-4-methylaminorex ((+)-cis-4,5-dihydro-4-methyl-5-phenyl-2
28 -oxazolamine)] (±)CIS-4-METHYLAMINOREX ((±)CIS-4,5-DIHYDRO-4-METHYL-5-
29 PHENYL-2-OXAZOLAMINE);

30 (7) N-ethylamphetamine; and

1 (8) N, N-dimethylamphetamine.

2 (g) Unless specifically excepted under this subtitle or listed in another schedule,
3 any material, compound, mixture, or preparation that contains any quantity of the
4 following substances, or that contains their salts, isomers, or salts of isomers, whenever the
5 existence of such salts, isomers, or salts of isomers is possible within the specific chemical
6 designation, is a substance listed in Schedule I:

7 (1) 5-(1, 1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
8 (CP- 47,497);

9 (2) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP
10 - 47,497 C8 homolog);

11 (3) 1-pentyl-3-(1-naphthoyl) indole (JWH-018 and AM678);

12 (4) 1-butyl-3-(1-naphthoyl) indole (JWH-073);

13 (5) 1-hexyl-3-(1-naphthoyl) indole (JWH-019);

14 (6) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl) indole (JWH-200);

15 (7) 1-pentyl-3-(2-methoxyphenylacetyl) indole (JWH-250);

16 (8) 1-pentyl-3-[1-(4-methoxynaphthoyl)] indole (JWH-081);

17 (9) 1-pentyl-3-(4-methyl-1-naphthoyl) indole (JWH-122);

18 (10) 1-pentyl-3-(4-chloro-1-naphthoyl) indole (JWH-398);

19 (11) 1-(5-fluoropentyl)-3-(1-naphthoyl) indole (AM2201);

20 (12) 1-(5-fluoropentyl)-3-(2-iodobenzoyl) indole (AM694);

21 (13) 1-pentyl-3-[(4-methoxy)-benzoyl] indole (SR-19 and RCS-4);

22 (14) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl) indole 7008 (SR-18 and
23 RCS-8); and

24 (15) 1-pentyl-3-(2-chlorophenylacetyl) indole (JWH-203).

25 (h) (1) In this subsection:

26 (i) "controlled dangerous substance analogue" means a substance:

27 1. that has a chemical structure substantially similar to the
28 chemical structure of a controlled dangerous substance listed in Schedule I or Schedule II;

1 and

2 2. that has a stimulant, depressant, or hallucinogenic effect
3 on the central nervous system that is substantially similar to or greater than the stimulant,
4 depressant, or hallucinogenic effect on the central nervous system of a controlled dangerous
5 substance listed in Schedule I or Schedule II; but

6 (ii) “controlled dangerous substance analogue” does not include:

7 1. a controlled dangerous substance;

8 2. a substance for which there is an approved new drug
9 application; or

10 3. a substance exempted for investigational use under § 506
11 of the Federal Food, Drug, and Cosmetic Act.

12 (2) To the extent intended for human consumption, each controlled
13 dangerous substance analogue is a substance listed in Schedule I.

14 (i) The Department may not add a substance to Schedule I under § 5–202 of this
15 title unless the Department finds:

16 (1) a high potential for abuse of the substance;

17 (2) no accepted medical use in the United States for the substance; and

18 (3) a lack of accepted safety for use of the substance under medical
19 supervision.

20 5–403.

21 (a) Schedule II consists of each controlled dangerous substance:

22 (1) listed in this section;

23 (2) added to Schedule II by the Department under § 5–202(b) of this title;
24 or

25 (3) designated as a Schedule II controlled dangerous substance by the
26 federal government unless the Department objects under § 5–202(f) of this title.

27 (b) Unless specifically excepted or unless listed in another schedule, any of the
28 following substances whether produced directly or indirectly by extraction from substances
29 of vegetable origin, or independently by means of chemical synthesis, or by a combination
30 of extraction and chemical synthesis:

1 (1) opium and opiate, and any salt, compound, derivative, or preparation
2 of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan,
3 nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, and naltrexone, and their
4 respective salts, but including the following:

- 5 (i) codeine;
- 6 (ii) dihydroetorphine;
- 7 (iii) ethylmorphine;
- 8 (iv) etorphine hydrochloride;
- 9 (v) granulated opium;
- 10 (vi) hydrocodone;
- 11 (vii) hydromorphone;
- 12 (viii) metopon;
- 13 (ix) morphine;
- 14 (x) **NOROXYMORPHONE**;
- 15 **(XI)** opium extracts;
- 16 ~~[(xi)]~~ **(XII)** opium fluid;
- 17 ~~[(xii)]~~ **(XIII)** oripavine;
- 18 ~~[(xiii)]~~ **(XIV)** oxycodone;
- 19 ~~[(xiv)]~~ **(XV)** oxymorphone;
- 20 ~~[(xv)]~~ **(XVI)** powdered opium;
- 21 ~~[(xvi)]~~ **(XVII)** raw opium;
- 22 ~~[(xvii)]~~ **(XVIII)** thebaine; and
- 23 ~~[(xviii)]~~ **(XIX)** tincture of opium;

24 (2) any salt, compound, derivative, or preparation thereof which is
25 chemically equivalent or identical with any of the substances referred to in item (1) of this

1 subsection, except that these substances may not include the isoquinoline alkaloids of
2 opium;

3 (3) opium poppy and poppy straw;

4 (4) coca leaves and any salt, compound, derivative, or preparation of coca
5 leaves, including cocaine and ecgonine and their salts, isomers, derivatives and salts of
6 isomers and derivatives, and any salt, compound, derivative, or preparation thereof which
7 is chemically equivalent or identical with any of these substances, except that the
8 substances may not include:

9 (i) decocainized coca leaves or extraction of coca leaves, which
10 extractions do not contain cocaine or ecgonine; or

11 (ii) ioflupane; and

12 (5) concentrate of poppy straw (the crude extract of poppy straw in either
13 liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium
14 poppy).

15 (c) Unless specifically excepted or unless in another schedule any of the following
16 opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers
17 whenever the existence of such isomers, esters, ethers, and salts is possible within the
18 specific chemical designation, dextrophan and levopropoxyphene excepted:

19 (1) alfentanil;

20 (2) alphaprodine;

21 (3) anileridine;

22 (4) bezitramide;

23 (5) bulk dextropropoxyphene (non-dosage forms);

24 (6) carfentanil;

25 (7) dihydrocodeine;

26 (8) diphenoxylate;

27 (9) fentanyl;

28 (10) isomethadone;

29 (11) levo-alphaacetylmethadol;

- 1 (12) levomethorphan;
- 2 (13) levorphanol;
- 3 (14) metazocine;
- 4 (15) methadone;
- 5 (16) methadone – intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl
6 butane;
- 7 (17) moramide – intermediate, 2-methyl-3-morpholino-1, 1
8 – diphenylpropane-carboxylic acid;
- 9 (18) **OLICERIDINE (N-[(3-METHOXYTHIOPHEN-2-YL)METHYL]**
10 **{2-[(9R)-9-(PYRIDIN-2-YL)-6-OXASPIRO [4.5]DECAN-9-YL]ETHYL}AMINE**
11 **FUMARATE);**
- 12 (19) pethidine (meperidine);
- 13 [(19)] (20) pethidine – intermediate – A, 4-cyano-1-methyl-4
14 – phenylpiperidine;
- 15 [(20)] (21) pethidine – intermediate – B, ethyl-4-phenylpiperidine-4
16 – carboxylate;
- 17 [(21)] (22) pethidine – intermediate – C, 1-methyl-4-phenylpiperidine-4
18 – carboxylic acid;
- 19 [(22)] (23) phenazocine;
- 20 [(23)] (24) piminodine;
- 21 [(24)] (25) racemethorphan;
- 22 [(25)] (26) racemorphan;
- 23 [(26)] (27) remifentanil;
- 24 [(27)] (28) sulfentanil;
- 25 [(28)] (29) tapentadol; and
- 26 [(29)] (30) thiafentanil.

1 (d) Unless specifically excepted under this subtitle or listed in another schedule,
2 a substance is listed in Schedule II if the substance includes a material, compound, mixture,
3 or preparation that contains any quantity of the following substances having a potential
4 for abuse associated with a stimulant effect on the central nervous system:

- 5 (1) amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 6 (2) methamphetamine, its salts, isomer, and salts of isomers;
- 7 (3) phenmetrazine and its salts;
- 8 (4) methylphenidate; and
- 9 (5) lisdexamfetamine, its salts, isomers, and salts of isomers.

10 (e) Unless specifically excepted under this subtitle or listed in another schedule,
11 a substance is listed in Schedule II if the substance includes a material, compound, mixture,
12 or preparation that contains any quantity of the following substances having a depressant
13 effect on the central nervous system, including its salts, isomers, and salts of isomers
14 whenever the existence of such salts, isomers, and salts of isomers is possible within the
15 specific chemical designation:

- 16 (1) amobarbital;
- 17 (2) glutethimide;
- 18 (3) pentobarbital;
- 19 (4) phencyclidine; and
- 20 (5) secobarbital.

21 (f) **[As] HALLUCINOGENIC SUBSTANCES, AS** listed in Schedule II under Title
22 21 of the Code of Federal Regulations.

- 23 (1) nabilone; and

24 (2) dronabinol [(–)-delta-9-trans tetrahydrocannabinol] in an oral
25 solution in a drug product approved for marketing by the United States Food and Drug
26 Administration.

27 (g) Unless specifically excepted or unless listed in another schedule, any material,
28 compound, mixture, or preparation which contains any quantity of the following
29 substances:

- 30 (1) immediate precursor to amphetamine and methamphetamine:

- 1 (i) phenylacetone; and
- 2 (ii) reserved;
- 3 (2) immediate precursors to phencyclidine (PCP):
- 4 (i) 1-phenylcyclohexylamine; and
- 5 (ii) 1-piperidinocyclohexanecarbonitrile (PCC); and
- 6 (3) immediate precursor to fentanyl:
- 7 (i) 4-anilino-N-phenethylpiperidine (ANPP); and
- 8 (ii) [reserved] **N-PHENYL-N-(PIPERIDIN-4-YL)PROPIONAMIDE**
- 9 **(NORFENTANYL)**.

10 (h) The Department may not add a substance to Schedule II under § 5-202 of this

11 title unless the Department finds:

- 12 (1) a high potential for abuse of the substance;
- 13 (2) currently accepted medical use of the substance in the United States,
- 14 or currently accepted medical use with severe restrictions; and
- 15 (3) evidence that abuse of the substance may lead to severe psychological
- 16 or physical dependence.

17 5-404.

18 (a) Schedule III consists of each controlled dangerous substance by whatever

19 official name, common or usual name, chemical name, or brand name designated:

- 20 (1) listed in this section;
- 21 (2) added to Schedule III by the Department under § 5-202(b) of this title;
- 22 or
- 23 (3) designated as a Schedule III controlled dangerous substance by the
- 24 federal government unless the Department objects under § 5-202(f) of this title.

25 (b) (1) Unless specifically excepted or listed in another schedule, a substance

26 is listed in Schedule III if the substance includes a material, compound, mixture, or

27 preparation that contains any quantity of the following substances having a stimulant

28 effect on the central nervous system:

- 29 (i) those compounds, mixtures, or preparations in dosage unit form

1 containing any stimulant substances listed in Schedule II, which compounds, mixtures, or
2 preparations were listed on August 25, 1971, as excepted compounds under § 1308.32 of the
3 Code of Federal Regulations, and any other drug of the quantitative composition shown in
4 that list for those drugs or that is the same except that it contains a lesser quantity of
5 controlled substances;

6 (ii) benzphetamine;

7 (iii) chlorphentermine;

8 (iv) clortermine; and

9 (v) phendimetrazine.

10 (2) Subject to paragraph (3) of this subsection, substances in Schedule III
11 include:

12 (i) a salt of a substance listed in this subsection;

13 (ii) an optical, position, or geometric isomer of a substance listed in
14 this subsection; or

15 (iii) a salt of an isomer of a substance listed in this subsection.

16 (3) Unless listed in another schedule, a salt, isomer, or salt of an isomer
17 described in paragraph (2) of this subsection may be included in Schedule III only if the
18 existence of the salts, isomers, and salts of isomers is possible within the specific chemical
19 designation.

20 (c) Unless listed in another schedule, a substance is listed in Schedule III if the
21 substance includes a material, compound, mixture, or preparation that contains any
22 quantity of the following substances having a potential for abuse associated with a
23 depressant effect on the central nervous system:

24 (1) any compound, mixture, or preparation containing:

25 (i) amobarbital;

26 (ii) secobarbital;

27 (iii) pentobarbital; or

28 (iv) any salt thereof and one or more other active medicinal
29 ingredients that are not listed in any schedule;

30 (2) any suppository dosage form containing:

- 1 (i) amobarbital;
- 2 (ii) secobarbital;
- 3 (iii) pentobarbital; or
- 4 (iv) any salt of any of these drugs and approved by the U.S. Food and
5 Drug Administration for marketing only as a suppository;
- 6 (3) except those substances that are specifically listed in other schedules,
7 a substance that contains any quantity of a derivative of barbituric acid, a salt of a
8 derivative of a barbituric acid, or butalbital, including, with one or more active, nonnarcotic
9 ingredients in recognized therapeutic amounts, (Fioricet) and (Fiorinal);
- 10 (4) chlorhexadol;
- 11 (5) embutramide;
- 12 (6) any drug product containing gamma hydroxybutyric acid, including its
13 salts, isomers, and salts of isomers, for which an application is approved under Section 505
14 of the Federal Food, Drug, and Cosmetic Act;
- 15 (7) ketamine, its salts, isomers, and salts of isomers;
- 16 (8) lysergic acid;
- 17 (9) lysergic acid amide;
- 18 (10) methyprylon;
- 19 (11) perampanel, and its salts, isomers, and salts of isomers (FYCOMPA);
- 20 (12) sulfondiethylmethane;
- 21 (13) sulfonethylmethane;
- 22 (14) sulfonmethane; and
- 23 (15) tiletamine and zolazepam or any salt thereof, including a
24 tiletamine–zolazepam combination product (trade name Telazol).
- 25 (d) As listed in Schedule III under Title 21 of the Code of Federal Regulations,
26 nalorphine 9400.
- 27 (e) Unless specifically excepted or unless listed in another schedule:
- 28 (1) substances listed in Schedule III include any material, compound,

1 mixture, or preparation containing any of the following narcotic drugs, or their salts
2 calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

3 (i) not more than 1.80 grams of codeine per 100 milliliters or not
4 more than 90 milligrams per dosage unit, with an equal or greater quantity of an
5 isoquinoline alkaloid of opium;

6 (ii) not more than 1.80 grams of codeine per 100 milliliters or not
7 more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients
8 in recognized therapeutic amounts;

9 (iii) not more than 1.80 grams of dihydrocodeine per 100 milliliters
10 or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic
11 ingredients in recognized therapeutic amounts;

12 (iv) not more than 300 milligrams of ethylmorphine per 100
13 milliliters or not more than 15 milligrams per dosage unit, with one or more active,
14 nonnarcotic ingredients in recognized therapeutic amounts;

15 (v) not more than 500 milligrams of opium per 100 milliliters or per
16 100 grams, or not more than 25 milligrams per dosage unit, with one or more active,
17 nonnarcotic ingredients in recognized therapeutic amounts;

18 (vi) not more than 100 milligrams of opium per 100 milliliters or per
19 100 grams, or not more than 5 milligrams per dosage unit; and

20 (vii) not more than 50 milligrams of morphine per 100 milliliters or
21 per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic
22 amounts.

23 (2) any material, compound, mixture, or preparation containing any of the
24 following narcotic drugs or their salts, as set forth below:

25 (i) buprenorphine; and

26 (ii) reserved.

27 (3) if not combined with one or more active medicinal ingredients that are
28 listed in another schedule, substances listed in Schedule III include a suppository dosage
29 form or salt of a suppository dosage that contains:

30 (i) amobarbital;

31 (ii) secobarbital; or

32 (iii) pentobarbital.

- 1 (f) (1) Except as provided in paragraph (2) of this subsection, an anabolic
2 steroid consisting of any material, compound, mixture, or preparation containing any
3 quantity of the following substances, including its salts, esters, and ethers:
- 4 (i) 3beta,17-dihydroxy-5a-androstane;
 - 5 (ii) 3alpha,17beta-dihydroxy-5a-androstane;
 - 6 (iii) 5 alpha-androstan-3,17-dione;
 - 7 (iv) 1-androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1
8 -ene);
 - 9 (v) 1-androstenediol (3alpha,17beta-dihydroxy-5alpha-androst
10 -1-ene);
 - 11 (vi) 4-androstenediol (3beta,17beta-dihydroxy-androst-4-ene);
 - 12 (vii) 5-androstenediol (3beta,17beta-dihydroxy-androst-5-ene);
 - 13 (viii) 1-androstenedione;
 - 14 (ix) 4-androstenedione;
 - 15 (x) 5-androstenedione;
 - 16 (xi) bolasterone;
 - 17 (xii) boldenone;
 - 18 (xiii) boldione;
 - 19 (xiv) calusterone;
 - 20 (xv) chlorotestosterone (clostebol);
 - 21 (xvi) dehydrochloromethyltestosterone;
 - 22 (xvii) desoxymethyltestosterone;
 - 23 (xviii) delta1-dihydrotestosterone (17beta-hydroxy-5alpha-androst
24 -1-en-3-one);
 - 25 (xix) dihydrotestosterone (4-dihydrotestosterone) (17beta-hydroxy
26 - androstan-3-one) (stanolone);
 - 27 (xx) drostanolone;

- 1 (xxi) ethylestrenol;
- 2 (xxii) fluoxymesterone;
- 3 (xxiii) formebolone;
- 4 (xxiv) furazabol;
- 5 (xxv) 13beta-ethyl-17beta-hydroxygon-4-en-3-one;
- 6 (xxvi) 4-hydroxytestosterone;
- 7 (xxvii) 4-hydroxy-19-nortestosterone;
- 8 (xxviii) mestanolone (17alpha-methyl-17beta-hydroxy-5
9 -androstane-3-one);
- 10 (xxix) mesterolone;
- 11 (xxx) methandienone (methandrostenolone) (17alpha-methyl
12 -17beta-hydroxyandrost-1,4-dien-3-one);
- 13 (xxxi) methandriol;
- 14 (xxxii) methasterone;
- 15 (xxxiii) methenolone;
- 16 (xxxiv) 17alpha-methyl-3beta, 17beta-dihydroxy-5a
17 -androstane;
- 18 (xxxv) 17alpha-methyl-3alpha, 17beta-dihydroxy-5a-androstane;
- 19 (xxxvi) 17alpha-methyl-3beta, 17beta-dihydroxyandrost-4-ene;
- 20 (xxxvii) 17alpha-methyl-4-hydroxynandrolone;
- 21 (xxxviii) methyldienolone;
- 22 (xxxix) methyltrienolone;
- 23 (xl) methyltestosterone;
- 24 (xli) mibolerone;
- 25 (xlii) 17alpha-methyl-delta1-dihydrotestosterone;

- 1 (xliii) nandrolone;
- 2 (xliv) 19-nor-4-androstenediol (3beta, 17beta-dihydroxyestr-4-ene);
- 3 (xlv) 19-nor-4-androstenediol (3alpha, 17beta-dihydroxyestr-4
4 -ene);
- 5 (xlvi) 19-nor-5-androstenediol (3beta, 17beta-dihydroxyestr-5-ene);
- 6 (xlvii) 19-nor-5-androstenediol (3alpha, 17beta-dihydroxyestr-5
7 -ene);
- 8 (xlviii) 19-nor-4,9(10)-androstadienedione;
- 9 (xlix) 19-nor-4-androstenedione;
- 10 (l) 19-nor-5-androstenedione;
- 11 (li) norbolethone (13beta, 17alpha-diethyl-17beta-hydroxygon-4
12 -en-3-one);
- 13 (lii) norclostebol;
- 14 (liii) norethandrolone;
- 15 (liv) normethandrolone;
- 16 (lv) oxandrolone;
- 17 (lvi) oxymesterone;
- 18 (lvii) oxymetholone;
- 19 (lviii) prostanazol;
- 20 (lix) stanozolol;
- 21 (lx) stenbolone;
- 22 (lxi) testolactone;
- 23 (lxii) testosterone;
- 24 (lxiii) tetrahydrogestrinone; and
- 25 (lxiv) trenbolone.

1 (2) The following substances are not included in Schedule III:

2 (i) an estrogen, progestin, [or] corticosteroid, OR
3 **DEHYDROEPIANDROSTERONE**; or

4 (ii) a substance covered by paragraph (1) of this subsection if:

5 1. expressly intended for administration through implants to
6 cattle or other nonhuman species; and

7 2. approved for that use by the U.S. Food and Drug
8 Administration.

9 (g) Hallucinogenic substances include:

10 (1) dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin
11 capsule in a U.S. Food and Drug Administration–approved product; and

12 (2) reserved.

13 (h) The Department may not add a substance to Schedule III under § 5–202 of
14 this title unless the Department finds:

15 (1) a potential for abuse of the substance that is less than that for the
16 substances listed in Schedule I and Schedule II;

17 (2) well documented and approved medical use of the substance in the
18 United States; and

19 (3) evidence that abuse of the substance may lead to moderate or low
20 physical dependence or high psychological dependence.

21 5–405.

22 (a) Schedule IV consists of each controlled dangerous substance:

23 (1) listed in this section;

24 (2) added to Schedule IV by the Department under § 5–202(b) of this title;
25 or

26 (3) designated as a Schedule IV controlled dangerous substance by the
27 federal government unless the Department objects under § 5–202(f) of this title.

28 (b) Unless specifically excepted or unless listed in another schedule, any material,
29 compound, mixture, or preparation containing any of the following narcotic drugs, or their

1 salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth
2 below:

3 (1) not more than 1 milligram of difenoxin and not less than 25 micrograms
4 of atropine sulfate per dosage unit;

5 (2) dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3
6 -methyl-2-propionoxybutane); and

7 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its
8 salts, optical and geometric isomers and salts of these isomers (including tramadol).

9 (c) Substances listed in Schedule IV include a material, compound, mixture, or
10 preparation that contains any quantity of the following substances having a potential for
11 abuse associated with a depressant effect on the central nervous system, including its salts,
12 isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of
13 isomers is possible within the specific chemical designations:

14 (1) alfaxalone;

15 (2) alprazolam;

16 (3) barbital;

17 (4) brexanolone;

18 (5) bromazepam;

19 (6) camazepam;

20 (7) carisoprodol;

21 (8) chloral betaine;

22 (9) chloral hydrate;

23 (10) chlordiazepoxide;

24 (11) clobazam;

25 (12) clonazepam;

26 (13) clorazepate;

27 (14) clotiazepam;

28 (15) cloxazolam;

- 1 (16) delorazepam;
- 2 (17) diazepam;
- 3 (18) dichloralphenazone;
- 4 (19) estazolam;
- 5 (20) ethchlorvynol;
- 6 (21) ethinamate;
- 7 (22) ethyl loflazepate;
- 8 (23) fludiazepam;
- 9 (24) flunitrazepam;
- 10 (25) flurazepam;
- 11 (26) fospropofol;
- 12 (27) halazepam;
- 13 (28) haloxazolam;
- 14 (29) ketazolam;
- 15 (30) **LEMBOREXANT;**
- 16 **(31)** loprazolam;
- 17 **[(31)] (32)** lorazepam;
- 18 **[(32)] (33)** lormetazepam;
- 19 **[(33)] (34)** mebutamate;
- 20 **[(34)] (35)** medazepam;
- 21 **[(35)] (36)** meprobamate;
- 22 **[(36)] (37)** methohexital;
- 23 **[(37)] (38)** methylphenobarbital (mephobarbital);

- 1 [(38)] **(39)** midazolam;
- 2 [(39)] **(40)** nimetazepam;
- 3 [(40)] **(41)** nitrazepam;
- 4 [(41)] **(42)** nordiazepam;
- 5 [(42)] **(43)** oxazepam;
- 6 [(43)] **(44)** oxazolam;
- 7 [(44)] **(45)** paraldehyde;
- 8 [(45)] **(46)** petrichloral;
- 9 [(46)] **(47)** phenobarbital;
- 10 [(47)] **(48)** pinazepam;
- 11 [(48)] **(49)** prazepam;
- 12 [(49)] **(50)** quazepam;
- 13 **(51) REMIMAZOLAM;**
- 14 [(50)] **(52)** suvorexant (Belsomra);
- 15 [(51)] **(53)** temazepam;
- 16 [(52)] **(54)** tetrazepam;
- 17 [(53)] **(55)** triazolam;
- 18 [(54)] **(56)** zaleplon (Sonata);
- 19 [(55)] **(57)** zolpidem (Ambien); and
- 20 [(56)] **(58)** zopiclone (Lunesta).

21 (d) Substances listed in Schedule IV include:

- 22 (1) a material, compound, mixture, or preparation that contains
23 fenfluramine; and

- 1 (2) if its existence is possible:
- 2 (i) a salt of fenfluramine;
- 3 (ii) an optical, position, or geometric isomer of fenfluramine,
4 including dexfenfluramine; and
- 5 (iii) a salt of an isomer of fenfluramine.
- 6 (e) Substances listed in Schedule IV include:
- 7 (1) a material, compound, mixture, or preparation that contains lorcaserin;
8 and
- 9 (2) if its existence is possible:
- 10 (i) a salt of lorcaserin;
- 11 (ii) an optical, position, or geometric isomer of lorcaserin; and
- 12 (iii) a salt of an isomer of lorcaserin.
- 13 (f) Substances listed in Schedule IV include a material, compound, mixture, or
14 preparation that contains any quantity of the following substances having a potential for
15 abuse associated with a stimulant effect on the central nervous system, including its salts,
16 isomers, and salts of isomers:
- 17 (1) cathine ((+)-norpseudoephedrine);
- 18 (2) diethylpropion;
- 19 (3) fencamfamin;
- 20 (4) fenproporex;
- 21 (5) mazindol;
- 22 (6) mefenorex;
- 23 (7) modafinil;
- 24 (8) pemoline, including organometallic complexes and their chelates;
- 25 (9) phentermine;
- 26 (10) pipradrol;

1 (11) **SERDEXMETHYLPHENIDATE;**

2 **(12)** sibutramine;

3 **[(12)] (13)** solriamfetol (2-amino-3-phenylpropyl carbamate;
4 benzenepropanol, beta-amino-, carbamate (ester)); and

5 **[(13)] (14)** SPA ((-)-1-dimethylamino-1,2-diphenylethane).

6 (g) Unless specifically excepted or unless listed in another schedule, any material,
7 compound, mixture, or preparation that contains any quantity of the following substances,
8 including its salts:

9 (1) pentazocine;

10 (2) butorphanol (including its optical isomers); and

11 (3) eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl]-2,
12 6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-
13 yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical isomers) and its
14 salts, isomers, and salts of isomers.

15 (h) By regulation, the Department may exempt from this section a compound,
16 mixture, or preparation that contains a depressant substance listed in subsection (c) of this
17 section if:

18 (1) the compound, mixture, or preparation contains an active medicinal
19 ingredient that does not have a depressant effect on the central nervous system; and

20 (2) the admixtures are included in combinations, quantity, proportion, or
21 concentration that vitiate the potential for abuse of the substances that have a depressant
22 effect on the central nervous system.

23 (i) The Department may not add a substance to Schedule IV under § 5-202 of
24 this title unless the Department finds that:

25 (1) the substance has a low potential for abuse relative to the substances
26 listed in Schedule III;

27 (2) the substance has currently accepted medical use in treatment in the
28 United States; and

29 (3) abuse of the substance may lead to limited physical dependence or
30 psychological dependence relative to the substances in Schedule III.

31 5-406.

1 (a) Schedule V consists of each controlled dangerous substance:

2 (1) listed in this section;

3 (2) added to Schedule V by the Department under § 5–202(b) of this title;
4 or

5 (3) designated as a Schedule V controlled dangerous substance by the
6 federal government unless the Department objects under § 5–202(f) of this title.

7 (b) Unless specifically excepted or unless listed in another schedule, any material,
8 compound, mixture, or preparation containing any of the following narcotic drugs and their
9 salts, as set forth below:

10 (1) reserved; and

11 (2) reserved.

12 (c) Any compound, mixture, or preparation containing any of the following
13 narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited
14 quantities as set forth below, which shall include one or more nonnarcotic active medicinal
15 ingredients in sufficient proportion to confer upon the compound, mixture, or preparation
16 valuable medicinal qualities other than those possessed by narcotic drugs alone:

17 (1) not more than 200 milligrams of codeine per 100 milliliters or per 100
18 grams;

19 (2) not more than 100 milligrams of dihydrocodeine per 100 milliliters or
20 per 100 grams;

21 (3) not more than 100 milligrams of ethylmorphine per 100 milliliters or
22 per 100 grams;

23 (4) not more than 2.5 milligrams of diphenoxylate and not less than 25
24 micrograms of atropine sulfate per dosage unit; or

25 (5) **NOT MORE THAN 0.5 MILLIGRAM OF DIFENOXIN AND NOT LESS**
26 **THAN 25 MICROGRAMS OF ATROPINE SULFATE PER DOSAGE UNIT (difenoxin**
27 **preparations 0.5mg/25ug ATSO4/DU (MOTOFEN)).**

28 (d) Unless specifically exempted or excluded or unless listed in another schedule,
29 any material, compound, mixture, or preparation that contains any quantity of the
30 following substances having a stimulant effect on the central nervous system, including its
31 salts, isomers, and salts of isomers:

32 (1) pyrovalerone; and

1 (2) reserved.

2 (e) Unless specifically exempted or excluded or unless listed in another schedule,
3 any material, compound, mixture, or preparation that contains any quantity of the
4 following substances having a depressant effect on the central nervous system, including
5 its salts:

6 (1) brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]
7 butanamide) (Briviact);

8 (2) CENOBAMATE **[[(1R)-1-(2-CHLOROPHENYL)-2-(TETRAZOL-2-
9 -YL)ETHYL] CARBAMATE; 2H-TETRAZOLE-2-ETHANOL, ALPHA-(2
10 -CHLOROPHENYL)-, CARBAMATE (ESTER), (ALPHA R)-; CARBAMIC ACID (R)-(+)-1
11 -(2-CHLOROPHENYL)-2-(2H-TETRAZOL-2-YL)ETHYL ESTER];**

12 (3) ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]
13 -carbamic acid ethyl ester] (Potiga);

14 [(3) (4) lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy
15 -propionamide] (Vimpat); [and]

16 (5) LASMIDITAN **[2,4,6-TRIFLUORO-N-(6-(1-METHYLPIPERIDINE
17 -4-CARBONYL)PYRIDINE-2-YL-BENZAMIDE)]; AND**

18 [(4) (6) pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid]
19 (Lyrica).

20 [(f) A drug product in finished dosage formulation that has been approved by the
21 United States Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl
22 -6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from
23 cannabis and no more than 0.1% (w/w) residual tetrahydrocannabinols.]

24 [(g) (F) The Department may not add a substance to Schedule V under § 5-202
25 of this title unless the Department finds:

26 (1) the substance has a low potential for abuse relative to the substances
27 listed in Schedule IV;

28 (2) the substance has currently accepted medical use in the United States;
29 and

30 (3) abuse of the substance may lead to limited physical dependence or
31 psychological dependence liability relative to the substances listed in Schedule IV.

32 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect

1 October 1, 2022.